X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (106) 106
female (75) 75
male (74) 74
adult (68) 68
middle aged (66) 66
index medicus (62) 62
aged (51) 51
orvostudományok (50) 50
klinikai orvostudományok (48) 48
hematology (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (33) 33
chemotherapy (32) 32
oncology (30) 30
survival (28) 28
adolescent (27) 27
prognosis (26) 26
hodgkin disease - pathology (24) 24
lymphoma (24) 24
treatment outcome (24) 24
disease (23) 23
hodgkin disease - drug therapy (23) 23
hodgkin's disease (22) 22
lymphomas (22) 22
hodgkin lymphoma (21) 21
hodgkin disease - therapy (19) 19
pathology (19) 19
diagnosis (18) 18
medicine, general & internal (18) 18
rituximab (18) 18
aged, 80 and over (17) 17
retrospective studies (17) 17
therapy (17) 17
young adult (17) 17
immunology (16) 16
hodgkin disease - complications (14) 14
hodgkin disease - radiotherapy (14) 14
hungary - epidemiology (14) 14
neoplasm staging (14) 14
patients (14) 14
survival analysis (14) 14
biomedicine (13) 13
cancer (13) 13
doxorubicin - administration & dosage (13) 13
hungary (13) 13
cancer research (12) 12
disease-free survival (12) 12
follow-up studies (12) 12
hodgkin disease - mortality (12) 12
risk factors (12) 12
antineoplastic combined chemotherapy protocols - administration & dosage (11) 11
bleomycin - administration & dosage (11) 11
child (11) 11
medicine & public health (11) 11
recurrence (11) 11
relapse (11) 11
bortezomib (10) 10
hodgkin's lymphoma (10) 10
identification (10) 10
radiotherapy (10) 10
surgery (10) 10
vincristine - administration & dosage (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
biomedicine general (9) 9
care and treatment (9) 9
cyclophosphamide - administration & dosage (9) 9
expression (9) 9
human necessities (9) 9
hygiene (9) 9
medical or veterinary science (9) 9
prednisone - administration & dosage (9) 9
prevalence (9) 9
quality of life (9) 9
remission induction (9) 9
time factors (9) 9
transplantation, autologous (9) 9
hematopoietic stem cell transplantation (8) 8
hodgkin disease - diagnosis (8) 8
incidence (8) 8
leukemia (8) 8
multiple myeloma (8) 8
survival rate (8) 8
bandages, dressings or absorbent pads (7) 7
dacarbazine - administration & dosage (7) 7
devices providing patency to, or preventing collapsing of,tubular structures of the body, e.g. stents (7) 7
diagnosis, differential (7) 7
filters implantable into blood vessels (7) 7
first-aid kits (7) 7
fomentation (7) 7
further section (7) 7
immunohistochemistry (7) 7
non-hodgkin's lymphoma (7) 7
original paper (7) 7
orthopaedic, nursing or contraceptive devices (7) 7
physics (7) 7
prostheses (7) 7
safety (7) 7
t cells (7) 7
treatment (7) 7
treatment or protection of eyes or ears (7) 7
vinblastine - administration & dosage (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pathology & Oncology Research, ISSN 1219-4956, 10/2019, Volume 25, Issue 4, pp. 1615 - 1620
Ixazomib-Revlimid-Dexamethasone is an all-oral treatment protocol for multiple myeloma with a manageable tolerability profile which was available through a... 
Biomedicine, general | Pathology | Biomedicine | Immunology | Named patient program | Relapsed | Multiple myeloma | Cancer Research | Oncology | Ixazomib | Refractory materials | Dexamethasone | Embolisms | Medical services | Patients | Survival | Cytogenetics | Original
Journal Article
International Journal of Hematology, ISSN 0925-5710, 11/2019, Volume 110, Issue 5, pp. 559 - 565
Daratumumab is a human anti-CD38 monoclonal antibody used in the treatment of refractory and relapsed multiple myeloma. We investigated the efficacy and safety... 
Medicine & Public Health | Hematology | Toxicity | Daratumumab | Multiple myeloma | Oncology | Treatment response | Survival | Care and treatment | Refractory materials | Infusion | Renal function | Bortezomib | CD38 antigen | Monoclonal antibodies | Safety
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 297 - 311
Journal Article
by Horwitz, Steven and O'Connor, Owen A and O'Connor, Owen and Pro, Barbara and Illidge, Tim and Fanale, Michelle and Advani, Ranjana and Bartlett, Nancy and Bartlett, Nancy L and Christensen, Jacob Haaber and Morschhauser, Franck and Domingo-Domenech, Eva and Rossi, Giuseppe and Kim, Won Seog and Feldman, Tatyana and Lennard, Anne and Belada, David and Illés, Árpád and Tobinai, Kensei and Tsukasaki, Kunihiro and Yeh, Su-Peng and Shustov, Andrei and Hüttmann, Andreas and Savage, Kerry and Savage, Kerry J and Yuen, Sam and Iyer, Swaminathan and Zinzani, Pier Luigi and Hua, Zhaowei and Little, Meredith and Rao, Shangbang and Woolery, Joseph and Manley, Thomas and Trümper, Lorenz and Aboulafia, David and Alpdogan, Onder and Ando, Kiyoshi and Arcaini, Luca and Baldini, Luca and Bellam, Naresh and Yehuda, Dina Ben and Benedetti, Fabio and Borchman, Peter and Bordessoule, Dominique and Brice, Pauline and Briones, Javier and Caballero, Dolores and Carella, Angelo Michele and Chang, Hung and Cheong, June Weon and Cho, Seok-Goo and Choi, Ilseung and Choquet, Sylvain and Colita, Andrei and Congui, Angela Giovanna and D'amore, Francesco and Dang, Nam and Davison, Kelly and de Guibert, Sophie and Brown, Peter de Nully and Delwail, Vincent and Demeter, Judit and di Raimondo, Francesco and Do, Young Rok and Domingo, Eva and Douvas, Michael and Dreyling, Martin and Ernst, Thomas and Fay, Keith and Ferrero, Silvia Fernandez and Flinn, Ian Winchester and Forero-Torres, Andres and Fox, Christopher and Friedberg, Jonathan and Fukuhara, Noriko and Garcia-Marco, Jose and Cruz, Jorge Gayoso and Codina, Jose Gomez and Gressin, Remy and Grigg, Andrew and Gurion, Ronit and Haioun, Corinne and Hajek, Roman and Hanel, Mathias and Hatake, Kiyohiko and Hensen, Robert and Horowitz, Netanel and Huttmann, Andreas and Illes, Arpad and Ishizawa, Kenichi and Islas-Ohlmayer, Miguel and Jacobsen, Eric and Janakiram, Murali and Jurczak, Wojciech and Kaminski, Mark and Kato, Koji and Kirgner, Ilya and Kuo, Ching-Yuan and Lazaroiu, Mihaela Cornelia and Du, Katell Le and ... and ECHELON 2 Study Grp and ECHELON-2 Study Group
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 229 - 240
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 4, pp. 331 - 344
BACKGROUND Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma. METHODS We... 
TRIAL | ABVD | MEDICINE, GENERAL & INTERNAL | POSITRON-EMISSION-TOMOGRAPHY | RESPONSE CRITERIA | DISEASE | PROGNOSTIC SCORE | OPEN-LABEL | TOXICITY | INTERGROUP | COOPERATIVE-ONCOLOGY-GROUP | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Immunoconjugates - administration & dosage | Young Adult | Aged, 80 and over | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Immunoconjugates - adverse effects | Dacarbazine - administration & dosage | Immunologic Factors - administration & dosage | Survival Rate | Bleomycin - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Immunologic Factors - adverse effects | Neoplasm Staging | Vinblastine | Hematology | Toxicity | Prophylaxis | Clinical trials | Oncology | Peripheral neuropathy | Cancer therapies | Doxorubicin | Survival | Lymphoma | Medicine | Dacarbazine | Chemotherapy | Bleomycin | CD30 antigen | Granulocyte colony-stimulating factor | Death | Colony-stimulating factor | Lymphomas | Leukocytes (granulocytic) | Drug dosages | Hodgkin's disease | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Orvosi Hetilap, ISSN 0030-6002, 07/2016, Volume 157, Issue 31, pp. 1232 - 1241
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 05/2018, Volume 144, Issue 5, pp. 935 - 943
Purpose Majority of relapses in Hodgkin lymphoma (HL) occur within 3 years after initial treatment, late relapses (LR), happening 5 or more years after first... 
ABVD | Late relapse | Early relapse | Overall survival | Risk factors | Hodgkin lymphoma | TRIALS | 1ST REMISSION | CLASSIFICATION | COMMITTEE | WORLD-HEALTH-ORGANIZATION | ONCOLOGY | DISEASE | SURVEILLANCE | RECURRENCE | Relapse | Youth | Lymphomas | Teenagers | Health aspects | Diseases
Journal Article
Histopathology, ISSN 0309-0167, 04/2019, Volume 74, Issue 5, pp. 699 - 708
Aims The present study evaluates the impact of hypoxia‐related carbonic anhydrase IX and XII isoenzyme expression as a basic adaptive mechanism to neutralise... 
hypoxia | adaptation | cell cycle | resistance | survival | Hodgkin's lymphoma | REED-STERNBERG CELLS | PROLIFERATION | PATHOLOGY | CANCER | CELL BIOLOGY | KI-67 | MIB-1 | DISEASE | REGULATORS | PROGNOSTIC-SIGNIFICANCE | INDEX | Immunohistochemistry | Enzymes | Lymphomas | Cell proliferation | Phenotypes | Cell survival | Cell membranes | Lymphoma | Sclerosis | Chemotherapy | Cell growth | Hypoxia | Acidosis | Hodgkin's disease
Journal Article
Pathology and Oncology Research, ISSN 1219-4956, 2018, pp. 1 - 6
Multiple myeloma is quite uncommon in the young population. We performed a retrospective review in our database from 2006 to 2015 to examine the clinical... 
Young | 40 years | Overall survival | Progression-free survival | Multiple myeloma | Proteins | Autografts | Medical services | Stem cells | Stem cell transplantation | Transplantation | Patients | Survival
Journal Article
Cureus, ISSN 2168-8184, 12/2018, Volume 10, Issue 12, p. e3769
Therapy-related acute myeloid leukemia (t-AML) is most frequently observed after the use of alkylating agents and topoisomerase II inhibitors and is associated... 
Disease | Leukemia | Colorectal cancer | Cytotoxicity | Hybridization | Family medical history | Patients | Cancer therapies | Chemotherapy | Medical prognosis | Bone marrow | Chromosomes | Deoxyribonucleic acid--DNA
Journal Article
Blood, ISSN 0006-4971, 12/2018, Volume 132, Issue 23, pp. 2446 - 2455
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase delta and gamma (PI3K-delta,gamma) being developed for treatment... 
CLL | THERAPY | IDELALISIB | PI3K-DELTA,GAMMA | IBRUTINIB | CHRONIC LYMPHOCYTIC-LEUKEMIA | INHIBITOR | PI3K-GAMMA | COMBINATION | HEMATOLOGY | FLUDARABINE | Clinical Trials and Observations
Journal Article
Magyar onkologia, ISSN 0025-0244, 03/2015, Volume 59, Issue 1, p. 73
Successful treatment of lymphomas requires classical morphological diagnosis and also immunophenotyping as well as cytogenetics and molecular genetic... 
Lymphoma - drug therapy | Lymphoma - diagnosis | Prognosis | Biomarkers, Tumor - analysis | Humans | Lymphoma - genetics | Fluorodeoxyglucose F18 | Lymphoma - pathology | Tomography, X-Ray Computed | Biomarkers, Tumor - genetics | Positron-Emission Tomography - methods | Molecular Targeted Therapy
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3257 - 3257
Abstract Background: Daratumumab is one of the most effective new myeloma drugs recently approved for relapsed/refractory multiple myeloma (MM), first in... 
Journal Article
Journal Article